Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.5992 USD -2.11% Market Closed
Market Cap: 136.3m USD
Have any thoughts about
Vaxart Inc?
Write Note

Vaxart Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vaxart Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Vaxart Inc
NASDAQ:VXRT
Net Change in Cash
-$11.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-14%
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
-$669m
CAGR 3-Years
57%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
-$25.7B
CAGR 3-Years
N/A
CAGR 5-Years
-116%
CAGR 10-Years
-19%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$5.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
-$148.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vaxart Inc
Glance View

Market Cap
136.3m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
0.6663 USD
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Vaxart Inc's Net Change in Cash?
Net Change in Cash
-11.2m USD

Based on the financial report for Sep 30, 2024, Vaxart Inc's Net Change in Cash amounts to -11.2m USD.

What is Vaxart Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
-14%

Over the last year, the Net Change in Cash growth was 36%.

Back to Top